Down day for Tetraphase Pharma

|About: Tetraphase Pharmaceuti... (TTPH)|By:, SA News Editor

Demonstrating an annoying problem of holding a thinly-traded stock, shares of nano cap Tetraphase Pharmaceuticals (TTPH -13.9%) plummet on a 2x surge in volume, albeit only 354K shares, on no news.

On June 19, the company announced the completion of enrollment of its Phase 3 clinical trial for its lead product candidate eravacycline as a treatment for complicated urinary tract infections.